Precise Targeting of Autoantigen-Specific B Cells in Lupus Nephritis with Chimeric Autoantibody Receptor T Cells
暂无分享,去创建一个
T. Moliné | J. Cortés-Hernández | Cristina Solé | Maria Royo | Sebastian Sandoval | Alejandra Gabaldón
[1] J. Kreye,et al. Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells , 2023, Cell.
[2] Seyyed Mahmoud Hashemi,et al. Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: An in-vitro study , 2023, Heliyon.
[3] S. Cai,et al. Newly developed 3D in vitro models to study tumor–immune interaction , 2023, Journal of Experimental & Clinical Cancer Research.
[4] D. Richman,et al. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells , 2023, Nature Biotechnology.
[5] A. Ekici,et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus , 2022, Nature Medicine.
[6] A. Mackensen,et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. , 2021, The New England journal of medicine.
[7] F. Shirani,et al. High frequency of concurrent anti-C1q and anti-dsDNA but not anti-C3b antibodies in patients with Lupus Nephritis , 2021, Journal of immunoassay & immunochemistry.
[8] Weiren Huang,et al. Patient‐derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR‐T cells in vitro , 2021, Clinical & translational immunology.
[9] M. Clark,et al. Cellular aspects of the pathogenesis of lupus nephritis , 2020, Current opinion in rheumatology.
[10] A. Seifalian,et al. Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment? , 2020, Frontiers in Immunology.
[11] Linrong Lu,et al. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus , 2020, Cellular & Molecular Immunology.
[12] B. Rovin,et al. Update on Lupus Nephritis: Core Curriculum 2020. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[13] Fangkun Liu,et al. Organoids to study immune functions, immunological diseases and immunotherapy. , 2020, Cancer letters.
[14] Yuehong Chen,et al. Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases , 2019, Journal of immunology research.
[15] T. Chan,et al. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis—Role in Pathogenesis and Effect of Immunosuppressive Treatments , 2019, International journal of molecular sciences.
[16] Xiaoyan Cai,et al. Multiple Functions of B Cells in the Pathogenesis of Systemic Lupus Erythematosus , 2019, International journal of molecular sciences.
[17] Yumin Xia,et al. Anti-double Stranded DNA Antibodies: Origin, Pathogenicity, and Targeted Therapies , 2019, Front. Immunol..
[18] M. Radic,et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus , 2019, Science Translational Medicine.
[19] T. Margaritis,et al. Tubuloids derived from human adult kidney and urine for personalized disease modeling , 2019, Nature Biotechnology.
[20] B. Rovin,et al. B-cell therapy in lupus nephritis: an overview. , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[21] A. Doria,et al. Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus , 2018, Arthritis & rheumatology.
[22] J. Melenhorst,et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. , 2018, JCI insight.
[23] R. Levy,et al. Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.
[24] T. Chan,et al. Anti-dsDNA antibodies and resident renal cells - Their putative roles in pathogenesis of renal lesions in lupus nephritis. , 2017, Clinical immunology.
[25] Ming-hui Zhao,et al. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes , 2017, Nature Reviews Nephrology.
[26] A. Lanzavecchia,et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease , 2016, Science.
[27] Juan Shi,et al. Antibodies against C1q Are a Valuable Serological Marker for Identification of Systemic Lupus Erythematosus Patients with Active Lupus Nephritis , 2015, Disease markers.
[28] T. Chan,et al. Mechanisms of Kidney Injury in Lupus Nephritis – the Role of Anti-dsDNA Antibodies , 2015, Front. Immunol..
[29] Edwin A. Yates,et al. Heparan sulfate and heparin interactions with proteins , 2015, Journal of The Royal Society Interface.
[30] C. Fabrizio,et al. Systemic Lupus Erythematosus with and without Anti-dsDNA Antibodies: Analysis from a Large Monocentric Cohort , 2015, Mediators of inflammation.
[31] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[32] Xiao-ming Meng,et al. Inflammatory processes in renal fibrosis , 2014, Nature Reviews Nephrology.
[33] J. Grande,et al. The Pathogenesis of Lupus Nephritis , 2014, Journal of clinical & cellular immunology.
[34] K. Kinoshita,et al. Estimation of kidney injury molecule-1 (Kim-1) in patients with lupus nephritis , 2014, Lupus.
[35] I. Heijnen,et al. Anti-C1q Antibodies as a Follow-Up Marker in SLE Patients , 2013, PloS one.
[36] B. Diamond,et al. Anti-DNA antibodies cross-react with C1q. , 2013, Journal of autoimmunity.
[37] K. Hans,et al. A Single Dose of Rituximab Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and Function , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[38] D. Vanhecke,et al. Identification of a major linear C1q epitope allows detection of systemic lupus erythematosus anti-C1q antibodies by a specific peptide-based enzyme-linked immunosorbent assay. , 2012, Arthritis and rheumatism.
[39] A. Davidson,et al. Taming lupus—a new understanding of pathogenesis is leading to clinical advances , 2012, Nature Medicine.
[40] T. Marion,et al. Anti-DNA auto-antibodies initiate experimental lupus nephritis by binding directly to the glomerular basement membrane in mice , 2012, Kidney international.
[41] M. Petri,et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. , 2011, Arthritis and rheumatism.
[42] O. Rekvig,et al. Nephritogenic antibodies bind in glomeruli through interaction with exposed chromatin fragments and not with renal cross-reactive antigens , 2011, Autoimmunity.
[43] J. Berden,et al. Lupus nephritis: role of antinucleosome autoantibodies. , 2011, Seminars in nephrology.
[44] M. Petri,et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.
[45] W. Sui,et al. Expression and role of integrin-linked kinase and collagen IV in human renal allografts with interstitial fibrosis and tubular atrophy. , 2010, Transplant immunology.
[46] B. Diamond,et al. The role of B cells in lupus pathogenesis. , 2010, The international journal of biochemistry & cell biology.
[47] O. Rekvig,et al. Anti-dsDNA Antibodies Promote Initiation, and Acquired Loss of Renal Dnase1 Promotes Progression of Lupus Nephritis in Autoimmune (NZBxNZW)F1 Mice , 2009, PloS one.
[48] M. Nebuloni,et al. Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition. , 2009, Human pathology.
[49] A. Zwinderman,et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response , 2007, Annals of the rheumatic diseases.
[50] D. Isenberg,et al. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. , 2006, Rheumatology.
[51] A. Tzioufas,et al. Cross‐recognition between histones and La/SSB may account for anti‐DNA reactivity in SLE patients , 2005, Clinical and experimental immunology.
[52] V. Strand,et al. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. , 2005, Arthritis and rheumatism.
[53] C. Putterman,et al. Cross-reactivity of human lupus anti-DNA antibodies with α-actinin and nephritogenic potential , 2005 .
[54] M. Madaio,et al. Pathogenic autoantibodies in lupus nephritis , 2005, Lupus.
[55] Pat Metharom,et al. The significance of controlled conditions in lentiviral vector titration and in the use of multiplicity of infection (MOI) for predicting gene transfer events , 2004, Genetic vaccines and therapy.
[56] M. Vilardell‐Tarrés,et al. Antihistone and anti-double-stranded deoxyribonucleic acid antibodies are associated with renal disease in systemic lupus erythematosus. , 2004, The American journal of medicine.
[57] Rizgar A. Mageed,et al. Cross-reactivity and pathogenicity of anti-DNA autoantibodies in systemic lupus erythematosus , 2002, Lupus.
[58] D. Gladman,et al. Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.
[59] M. Monestier,et al. Lupus anti‐DNA autoantibodies cross‐react with a glomerular structural protein: a case for tissue injury by molecular mimicry , 2001, European journal of immunology.
[60] B. Hahn. Antibodies to DNA. , 1998, The New England journal of medicine.
[61] F. van Gompel,et al. Anti-DNA antibodies can bind to the glomerulus via two distinct mechanisms. , 1992, Kidney international.
[62] L. P. Van den Heuvel,et al. Cross-reactivity of monoclonal anti-DNA antibodies with heparan sulfate is mediated via bound DNA/histone complexes. , 1990, Journal of autoimmunity.
[63] L. van de Putte,et al. Cross-reactivity of human and murine anti-DNA antibodies with heparan sulfate. The major glycosaminoglycan in glomerular basement membranes. , 1986, The Journal of clinical investigation.
[64] J. Fries,et al. A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. , 1982, Arthritis and rheumatism.
[65] I. Mårtensson,et al. Autoantibodies: Focus on anti-DNA antibodies. , 2011, Self/nonself.
[66] D. Perazzo,et al. [Systemic lupus erythematosus]. , 1955, Prensa medica argentina.